- Home
- GOSS vs ASRT Comparison
GOSS vs ASRT Comparison
Compare GOSS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | ASRT |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 76.0M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GOSS | ASRT |
|---|---|---|
| Price | $0.19 | $23.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | $4.19 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 12.1M | 299.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $48,471,000.00 | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.60 |
| 52 Week High | $3.87 | $23.46 |
Technical Indicators
Market Signals| Indicator | GOSS | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.70 | 84.81 |
| Support Level | $0.16 | $0.75 |
| Resistance Level | $0.36 | N/A |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 11.84 | 100.00 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.